Caribou Biosciences, (id:8173 CRBU)

2.02 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 3:25:16 PM)

Exchange closed, opens in 18 hours 4 minutes

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• All

About Caribou Biosciences,

Market Capitalization 182.92M

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.